Navigation Links
Amylin to Present Data Showing Investigational Metreleptin Treatment Led to Long-Term Improvements in Diabetes and Lipid Control in Patients with Lipodystrophy
Date:4/15/2011

therapy to market."

Study Findings

The findings involve an analysis of 55 lipodystrophy patients who received metreleptin treatment – the largest lipodystrophy cohort reported to date. At baseline, 75 percent of patients had diabetes and were not achieving adequate glycemic control (A1C greater than or equal to 7 percent), and 75 percent of patients had hypertriglyceridemia (triglycerides greater than or equal to 200 mg/dL). Metreleptin treatment resulted in robust reductions from baseline in both measures, an effect that was evident within four months post treatment initiation and sustained for up to several years of treatment. In patients with diabetes, mean A1C decreased from 9.4 percent at baseline to under 7.0 percent at year three; in patients with hypertriglyceridemia at baseline, median triglyceride concentrations decreased from 500 mg/dL at baseline to under 200 mg/dL at year three.

Adverse events were generally consistent with known co-morbid conditions of lipodystrophy (pancreatitis, proteinuria, autoimmune/chronic hepatitis) or expected pharmacological effects of metreleptin (weight loss or insulin-induced hypoglycemia in the setting of improved insulin sensitivity in patients on high doses of insulin).

About Lipodystrophy

Lipodystrophy syndromes are characterized by abnormalities in adipose (fat) tissue distribution. Because patients with lipodystrophy do not have enough fat tissue, they typically also have a deficiency of leptin, a hormone secreted by fat cells that plays a key role in regulating metabolism. Beginning typically in childhood or adolescence, patients affected by lipodystrophy experience a loss of subcutaneous fat, which can result in multiple, often severe metabolic abnormalities, including extreme insulin resistance, very high triglyceride levels, difficult-to-control diabetes and hepatic steatosis (excess fat accumulation in the liver). These abnormalities put patients at a high r
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
4. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
5. Amylin Pharmaceuticals Reports Third Quarter Financial Results
6. Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDAs BYETTA(R) (Exenatide) Injection Update
7. Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
8. Amylin Pharmaceuticals to Webcast Year-End Financial Results
9. Amylin Highlights 2010 Corporate Priorities at J.P. Morgan Healthcare Conference
10. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
11. Amylin Pharmaceuticals to Present at The Barclays Capital 2010 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014  Chuma Holdings, Inc. (OTCBB:CHUM) ... and turnkey support services for the lawfully organized ... processed and approved the Company,s name and symbol ... Corporation will be known as Chuma Holdings, Inc. ... through a merger with the Company,s wholly-owned subsidiary, ...
(Date:8/29/2014)... , Aug. 29, 2014  A Boston Scientific ... study on stent removability and preliminary long term ... published in the August issue of the peer-reviewed ... 1 is being conducted in 11 countries ... covered self-expanding metal stents (FCSEMS) after extended indwell ...
(Date:8/29/2014)... Research and Markets has announced ... Report, 2014-2017" report to their offering. ... of reimbursement for medical expenses, the Chinese orthopedic instrument ... presenting a CAGR of 19.2% during 2009-2013. Trauma products, ... of orthopedic instruments in China , ...
Breaking Medicine Technology:CannaMed Announces Name Change and Trading Symbol Change 2CannaMed Announces Name Change and Trading Symbol Change 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4China Orthopedic Instrument Industry Report, 2014-2017 2
... Patch Formulation May Provide New Option for Clinicians Concerned ... Systemic Exposure When ... Alpharma Inc. (NYSE: ALO ),a leading global ... presented this week at the American Pain Society annual,meeting ...
... Inc.,(Nasdaq: ARNA ) announced today that Taisho ... of a drug candidate under a GPCR-focused,partnership with ... drug candidate is a novel oral compound intended ... "We are very happy to see our long-standing ...
Cached Medicine Technology:Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 2Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 3Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 4Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 5Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 6Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 7Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd. 2Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd. 3
(Date:9/1/2014)... 2014 "Women struggle with weight gain ... changes begin as early as 15, if not earlier. ... the ups and downs of hormone related weight gain. ... healthy sizes seems to rage against the hidden and ... in her 40's begin to face menopause and related ...
(Date:9/1/2014)... atrial fibrillation (AF) doubles the risk of stroke compared ... 6 000 patients presented at ESC Congress today by ... a simple clinical assessment of the type of AF ... Ischaemic stroke is the second cause of death in ... many more disabled patients each year. Annual direct health ...
(Date:9/1/2014)... 2014 Bioinformatics refers to an ... biological and genetic data. A major part of ... software tools to generate and process useful biological ... biological computation. While bioinformatics simply makes use of ... its related concepts, biological computation refers to the ...
(Date:9/1/2014)... Top10BestSEOHosting.com has recently compared many web hosting companies. ... is here to announce that JustHost, Bluehost and ... 2014. , JustHost ( http://www.justhost.com/track/seohosts ) provides new ... plan. The company’s approach to hosting is to ... and powerful enough for anyone to use. And ...
(Date:9/1/2014)... September 01, 2014 AttorneyOne.com, a recognized ... the latest information from the FDA on DePuy ... FDA announced on August 28, that specific lots of ... (Class I) as the device may reverse directions after ... Craniomaxillofacial (CMF) Distraction System is an implant used to ...
Breaking Medicine News(10 mins):Health News:Female Hormonal Imbalances - Can’t Seem to Shed Those Extra Pounds? Discussion with Medical Expert Dr. Clairborne on Dr. Carol Francis Talk Radio Today 2Health News:Female Hormonal Imbalances - Can’t Seem to Shed Those Extra Pounds? Discussion with Medical Expert Dr. Clairborne on Dr. Carol Francis Talk Radio Today 3Health News:Permanent AF doubles risk of stroke compared to paroxysmal AF 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 4Health News:Why Top10BestSEOHosting.com Calls Them Great Web Hosting Suppliers 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 3
... the common diarrhea-causing disease , WEDNESDAY, Jan. 27 (HealthDay ... lives of millions of children in developing nations who ... studies show. , A study conducted in Malawi and ... life-threatening rotavirus in infants by more than 61 percent. ...
... ... cancer charity partners with the Vehicle Donation Processing Center to provide financial assistance to ... ... has partnered with the Vehicle Donation Processing Center, Inc. to launch a vehicle and ...
... NEWTOWN, Pa. , Jan. 27 CONNEXION ... Rob Naticchia as Executive Vice President, Client Services. In ... and development of CXHC, including its Clinical CONNEXION and Publication ... 15 years of pharmaceutical marketing and sales experience.  Most recently, ...
... , , ... the poorest nation in the Western Hemisphere.  It has practically nothing.  Although ... stationed where the quake hit the hardest. , Orphans International Worldwide Haiti ... Province, survived the earthquake unscathed.  An upcoming benefit in New York ...
... Adults with chronic rhinosinusitis a debilitating inflammation of the ... back report significantly improved quality of life following ... study led by Oregon Health & Science University (OHSU). ... Otolaryngology Head and Neck Surgery . ...
... ... a devastating magnitude-7.0 earthquake rocked Haiti, the global humanitarian organization Save the Children has ... , ... January 27, 2010 -- Two weeks after a devastating magnitude-7.0 earthquake rocked Haiti, the ...
Cached Medicine News:Health News:Rotavirus Vaccine Could Save Millions of Children Worldwide 2Health News:Rotavirus Vaccine Could Save Millions of Children Worldwide 3Health News:Rotavirus Vaccine Could Save Millions of Children Worldwide 4Health News: The Breast Cancer Society Launches Vehicle Donation Program 2Health News: The Breast Cancer Society Launches Vehicle Donation Program 3Health News:Robert Naticchia Joins CONNEXION Healthcare as Executive Vice President, Client Services 2Health News:Orphans International Worldwide Haiti Near Jacmel to Grow After Earthquake 2Health News:Orphans International Worldwide Haiti Near Jacmel to Grow After Earthquake 3Health News:Orphans International Worldwide Haiti Near Jacmel to Grow After Earthquake 4Health News:Orphans International Worldwide Haiti Near Jacmel to Grow After Earthquake 5Health News:Surgery helps chronic sinusitis sufferers get relief 2Health News:Two Weeks After Haiti Quake, Save the Children Helps More Than 105,000 Children and Families with Food, Medicines, Basic Supplies 2Health News:Two Weeks After Haiti Quake, Save the Children Helps More Than 105,000 Children and Families with Food, Medicines, Basic Supplies 3
... offer a complete line of ... state-of-the-art monoclonal and monoclonal/polyclonal antibody-based ... of enteric pathogens in fecal ... for Clostridium difficile, Entamoeba histolytica, ...
... offer a complete line of ... state-of-the-art monoclonal and monoclonal/polyclonal antibody-based ... of enteric pathogens in fecal ... for Clostridium difficile, Entamoeba histolytica, ...
... Difficile Tox A/B II test is also ... Fecal-Quik-Prep device which greatly reduces the hands-on ... Tox A/B II testing. The Fecal-Quik-Prep device ... greatly reduces the amount of hands-on time ...
... products for autoimmune testing feature single-well ANA ... as specific reflex tests including dsDNA, and ... (Ro), SS-B (La), Scl-70 and Jo-1. In ... full line of products for Cardiolipins (IgA, ...
Medicine Products: